Yang Y, Chan WK (2021) Glycogen Synthase Kinase 3 Beta Regulates the Human Aryl Hydrocarbon Receptor Cellular Content and Activity. Int J Mol Sci 22 34198826

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

S436-p - AHR (human) ▲

Modsite: LRTKNGTsGkDsATT SwissProt Entrez-Gene Orthologous residues AHR (human): S436‑p, AHR (mouse): S430‑p, AHR (rat): S434‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), Hep3B (hepatic), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3B (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes tideglusib decrease lithium decrease siRNA decrease GSK3B shRNA Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  autophagy, induced, transcription, induced

S440-p - AHR (human) ▲

Modsite: NGTsGkDsATTsTLS SwissProt Entrez-Gene Orthologous residues AHR (human): S440‑p, AHR (mouse): W434‑p, AHR (rat): W438‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), Hep3B (hepatic), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3B (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes tideglusib decrease lithium decrease siRNA decrease GSK3B shRNA Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  autophagy, induced, transcription, induced

S444-p - AHR (human) ▲

Modsite: GkDsATTsTLSKDSL SwissProt Entrez-Gene Orthologous residues AHR (human): S444‑p, AHR (mouse): S438‑p, AHR (rat): S442‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), Hep3B (hepatic), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3B (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes tideglusib decrease lithium decrease siRNA decrease GSK3B shRNA Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  autophagy, induced, transcription, induced

S689-p - AHR (human) ▲

Modsite: SQEFPYKsEMDsMPY SwissProt Entrez-Gene Orthologous residues AHR (human): S689‑p, AHR (mouse): P691‑p, AHR (rat): S696‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), Hep3B (hepatic), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3B (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes tideglusib decrease lithium decrease siRNA decrease GSK3B shRNA Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  autophagy, induced, transcription, induced

S693-p - AHR (human) ▲

Modsite: PYKsEMDsMPYtQNF SwissProt Entrez-Gene Orthologous residues AHR (human): S693‑p, AHR (mouse): S695‑p, AHR (rat): S700‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), Hep3B (hepatic), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3B (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes tideglusib decrease lithium decrease siRNA decrease GSK3B shRNA Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  autophagy, induced, transcription, induced

T697-p - AHR (human) ▲

Modsite: EMDsMPYtQNFISCN SwissProt Entrez-Gene Orthologous residues AHR (human): T697‑p, AHR (mouse): T699‑p, AHR (rat): T704‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), Hep3B (hepatic), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3B (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes tideglusib decrease lithium decrease siRNA decrease GSK3B shRNA Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  autophagy, induced, transcription, induced

S723-p - AHR (human) ▲

Modsite: ELDYPMGsFEPsPYP SwissProt Entrez-Gene Orthologous residues AHR (human): S723‑p, AHR (mouse): D725‑p, AHR (rat): D730‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), Hep3B (hepatic), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3B (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes tideglusib decrease lithium decrease siRNA decrease GSK3B shRNA Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  autophagy, induced, transcription, induced

S727-p - AHR (human) ▲

Modsite: PMGsFEPsPYPtTSS SwissProt Entrez-Gene Orthologous residues AHR (human): S727‑p, AHR (mouse): S729‑p, AHR (rat): S734‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), Hep3B (hepatic), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3B (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes tideglusib decrease lithium decrease siRNA decrease GSK3B shRNA Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  autophagy, induced, transcription, induced

T731-p - AHR (human) ▲

Modsite: FEPsPYPtTSSLEDF SwissProt Entrez-Gene Orthologous residues AHR (human): T731‑p, AHR (mouse): T733‑p, AHR (rat): N738‑p Characterization Methods used to characterize site in vivo:  mutation of modification site Disease tissue studied:  breast cancer Relevant cell lines - cell types - tissues:  HeLa (cervical), Hep3B (hepatic), MCF-7 (breast cell) Cellular systems studied:  cell lines Species studied:  human Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes KINASE GSK3B (human) transfection of wild-type enzyme, pharmacological inhibitor of upstream enzyme, siRNA inhibition of enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes tideglusib decrease lithium decrease siRNA decrease GSK3B shRNA Downstream Regulation Effect of modification (function):  protein degradation, ubiquitination Effect of modification (process):  autophagy, induced, transcription, induced